Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanguine Biosciences

Latest From Sanguine Biosciences

What will become of the German antidiabetics market?

Yet another company – this time Novo Nordisk – has decided that it wouldn't be good business to sell its antidiabetic in Germany following a rocky ride through the AMNOG benefit assessment and pricing negotiations. While companies are worried about the future of treatments for chronic diseases in Germany, prescribers and health insurers are more sanguine and believe that German patients are not yet missing out on important innovations in the market.

Metabolic Disorders Germany

Aegerion sinks on 3Q Juxtapid sales, forecast

Aegerion Pharmaceuticals sank 41% to $20.19 per share on 31 October after the company revealed lower than expected third quarter sales and cut its full-year 2014 sales guidance due to increased discontinuation rates for Juxtapid (lomitapide) and reimbursement challenges in ex-US markets.


Germany's IQWiG verdict for Sovaldi sets scene for tough pricing negotiations

Gilead's Sovaldi (sofosbuvir) provides additional benefit in hepatitis C virus (HCV) patients, but that benefit is unquantifiable, according to Germany's health technology appraisal body, IQWiG. The institute's lukewarm evaluation sets the scene for difficult pricing negotiations for Gilead.

Cancer Germany

Industry keeps up the pressure on UK early access scheme; new 'promising innovation medicine' designation in sight

The life sciences industry in the UK is continuing to put pressure on the government in an effort to make it deliver on the much-vaunted but still-to-materialize early access to medicines scheme. There is speculation that an announcement on the scheme is not far off, with a new “promising innovation medicine” designation expected to be introduced as part of it.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Sanguine Corp.
    • Sanguine Corporation